Don’t settle for failure
The verifi® Prenatal Test uses proven NGS technology to provide accurate NIPT results with the lowest failure rate

What is test failure?
For noninvasive prenatal testing (NIPT), test failure indicates that no call chromosomal status can be made. This is an important factor in the reliability and clinical utility of NIPT. NIPT failure rates vary significantly based on the type of test used. Using whole-genome next-generation sequencing (NGS), the verifi Prenatal Test from Illumina achieves the lowest test failure rate in NIPT (Figure 1).

The impact of test failure
As test failure is really an inconclusive result, it can lead to increased anxiety on the part of the patient and the physician, and it can potentially lead to an increased number of follow-up invasive procedures to obtain information. Although ordering a second blood draw to repeat NIPT is an option, there are no guarantees that repeated NIPT will provide a result. In fact, as many as 65% of patients who receive a test failure result on their first draw fail to receive a conclusive result, even after factoring in repeat attempts.1,4

Whole-genome sequencing (WGS) methods for NIPT have lower test failure rates than other targeted methods. According to the Society for Maternal-Fetal Medicine (SMFM), “women with failed cfDNA tests are at an increased risk for aneuploidy, and therefore need careful counseling about further testing, including the offer of diagnostic testing.”2 With a lower test failure rate, whole-genome NGS-based assays are more likely to detect these aneuploidies the first time.

To learn more about NIPT using the verifi Prenatal Test, visit www.illumina.com/verifi.
References


The verifi® Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. (VHI) a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.

© 2016 Illumina, Inc. All rights reserved. Illumina, verifi, and the pumpkin orange color are trademarks of Illumina, Inc. and/or its affiliates in the US and/or other countries. All other names, logos, and other trademarks are the property of their respective owners. Pub. No. 1570-2015-028 Current as of 30 August 2016